In a Healio Video Perspective, Dr. Nandini Venkateswaran discusses real-world data on the use of Dextenza in patients with glaucoma. Data from over 10,000 patients collected through the IRIS registry showed comparable IOP outcomes after implantation with Dextenza in patients with and without a history of glaucoma. This data supports Dextenza as a viable treatment option for patients after surgery to manage ocular pain and inflammation. Dr. Venkateswaran presented this information at OSN New York and OSN New York Retina, disclosing her consulting role with Ocular Therapeutix.
Source link
Dextenza shows promising IOP outcomes in patients with glaucoma
